Nature Medicine
- 12, 1294 - 1300 (2006)
Published online: 22 October 2006; Corrected online: 27 October 2006 ; Corrected online: 21 July 2008 | doi:10.1038/nm1491
There is a Corrigendum (November 2007) associated with this Article.
There is a Corrigendum (August 2008) associated with this Article.
Genomic signatures to guide the use of chemotherapeuticsAnil Potti1, 2, Holly K Dressman1, 3, Andrea Bild1, 3, Richard F Riedel1, 2, Gina Chan4, Robyn Sayer4, Janiel Cragun4, Hope Cottrill4, Michael J Kelley2, Rebecca Petersen5, David Harpole5, Jeffrey Marks5, Andrew Berchuck1, 6, Geoffrey S Ginsburg1, 2, Phillip Febbo1, 2, 3, Johnathan Lancaster4 & Joseph R Nevins1, 2, 31
Duke Institute for Genome Sciences and Policy, Duke University, Box 3382, Durham, North Carolina 27710, USA
2
Department of Medicine, Duke University Medical Center, Box 31295, Durham, North Carolina 27710, USA
3
Department of Molecular Genetics and Microbiology, Duke University Medical Center, Box 3054, Durham, North Carolina 27710, USA
4
Division of Gynecologic Surgical Oncology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, Florida 33612, USA
5
Department of Surgery, Duke University Medical Center, Box 3627, Durham, North Carolina 27710, USA
6
Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, North Carolina 27710, USA
Correspondence should be addressed to Joseph R Nevins nevin001@mc.duke.edu Using in vitro drug sensitivity data coupled with Affymetrix microarray data, we developed gene expression signatures that predict sensitivity to individual chemotherapeutic drugs. Each signature was validated with response data from an independent set of cell line studies. We further show that many of these signatures can accurately predict clinical response in individuals treated with these drugs. Notably, signatures developed to predict response to individual agents, when combined, could also predict response to multidrug regimens. Finally, we integrated the chemotherapy response signatures with signatures of oncogenic pathway deregulation to identify new therapeutic strategies that make use of all available drugs. The development of gene expression profiles that can predict response to commonly used cytotoxic agents provides opportunities to better use these drugs, including using them in combination with existing targeted therapies.NOTE: In the version of this article initially published online, the affiliations of some authors were incorrectly listed. R.S. and J.C. should be affiliation 4, and the correct address for this affiliation should be Division of Gynecologic Surgical Oncology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, Florida 33612, USA. Also, "Center for Applied Genomics and Technology" should be omitted from affiliation 1. The error has been corrected for all versions of the article.
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated.
|
